Report outlining global weaknesses in preventing deadly diseases

NewsGuard 100/100 Score

Significant weaknesses undermine the global community's abilities to prevent, detect early, and respond efficiently to potentially deadly species-crossing microbes, such as the pandemic H1N1 influenza virus sweeping the globe, says a new report from the Institute of Medicine and National Research Council.  The report provides a detailed plan for establishing and funding a comprehensive, globally coordinated system to identify novel zoonotic disease threats as early as possible wherever they arise so appropriate measures can be taken to prevent significant numbers of human illnesses and deaths, and livestock losses. 

U.S. federal agencies -- particularly the U.S. Agency for International Development -- should spearhead efforts to develop this system and work with international partners to provide funding and technical assistance to build the expertise, equipment, and other components of zoonotic disease surveillance and response capabilities in countries worldwide, said the committee that wrote the report.  Species-jumping pathogens have caused more than 65 percent of infectious disease outbreaks in the past six decades, and have racked up more than $200 billion in economic losses worldwide over the past 10 years, the report notes.  The U.S. beef industry alone lost $11 billion over three years after the detection of one cow with "mad cow disease" in 2003. 

Greater integration of the human health and veterinary medicine sectors should be a key feature of this new system because the lack of coordination and communication between these groups results in missed opportunities to detect potential species-crossing pathogens and leads to less effective measures to contain diseases.  The report also recommends a fundamental shift in surveillance away from urgent, time-constrained reactions to individual diseases when they arise to a sustained focus on preventing the conditions for zoonotic agents to emerge and looking for signs of possible threats on an ongoing basis.

USAID should also lead an effort to identify sustainable funding sources to develop and maintain this new system.  Funding for surveillance traditionally has focused on individual diseases with disproportionate resources aimed at infections in humans compared with those in animals.  Moreover, development aid budgets tend to fluctuate with changes in leadership or priorities.  The effort to find sustainable funding should specifically consider a tax on internationally traded meat and meat products as one possible mechanism, although the pros and cons of all options must be weighed to determine which funding sources will work best, the report notes.

The U.S. government and other donor organizations should provide economic incentives and technical and medical assistance to encourage the reporting of outbreaks and to lessen the social and economic consequences.  Repercussions such as drops in trade and tourism and necessary culling of livestock can lead individuals and nations to conceal outbreaks. 

In addition, the report calls for the director general of the World Organization for Animal Health (OIE) to have the power to declare animal health emergencies and make public credible information it receives about animal disease outbreaks if national governments fail to provide information in a timely manner.  Greater transparency could improve control of animal diseases before they decimate livestock or wildlife or make large numbers of people sick.

"Developing an effective global system for detecting and responding to emerging zoonotic diseases is a tall order," said committee co-chair Gerald T. Keusch, associate provost for global health and associate dean for global health, School of Public Health, Boston University, Boston.  "However, given the political will and financial resources that have been marshaled time and again to respond to the individual 'disease du jour' as each has arisen, we believe it is possible to implement a sustainable, integrated human and veterinary disease surveillance system that is acceptable to all stakeholders.  And we must do so now." 

"Zoonotic diseases are like wildfires, which flare up unexpectedly and can take a significant toll on human and animal health and damage household livelihoods as well as national economies," said co-chair Marguerite Pappaioanou, executive director, Association of American Veterinary Medical Colleges, Washington, D.C.  "All too often, our reaction to these outbreaks has been to try containing a wildfire after it has gotten out of control.  We need a system that enables us to prevent the conditions for these disease flare-ups to occur in the first place and to spot them earlier when we can take more effective and measured actions to limit the damage."   

Many obstacles have stymied the development of a more collaborative and robust disease surveillance system, the report says, including the low priority given to health issues by political leaders in some countries, lack of sufficient financing and coordinated governance, and lack of cooperation and integration among human and animal health experts. 

Comments

  1. Josef Hlasny Josef Hlasny Czech Republic says:

    You wrote that the U.S. beef industry alone lost $11 billion in the three years after the detection of one cow with "mad cow disease" in 2003.However, these economic losses were unnecessary.  Why? Because mad cow disease (BSE) is not an infectious disease, so beef is safe in the all world.. In addition; the link between variant CJD, BSE and scrapie has been widely accepted although never proved!!! Two groups of eminent British scientists argued in 2001 over whether the "infectious agent" in BSE would kill 136,000 Britons or only a few thousand. And what is the reality- where is the truth, seven years later? The 1st vCJD cases were observed in 1995, and the peak number of deaths was 28 in the year 2000, followed by 20 in 2001, 17 in 2002, 18 in 2003, 9 in 2004, 5 in 2005, 5 in 2006, 5 in 2007, and only one so far in 2008." So these findings (2008) act in concert with Dr VENTERS theory (The epidemic that never was) published in 2001 (http://www.bmj.com/cgi/content/full/323/7317/858).

    Other neurodegenerative, Alzheimer's disease first showed up in medical records at about the same time that world meat consumption (high protein intake) began to rise. There is a direct correlation between the rates of meat consumption and the rates of Alzheimer's disease in various cultures across the world. In Africa and Asian countries (largely vegetarian India...) where meat consumption is relatively low, the rates of Alzheimer's disease are much lower than in the developed countries, where meat consumption is high. Animal studies (dog,rat) have shown that high protein intakes can result in development of symptoms and pathologic changes of magnesium (Mg) deficiency on Mg-intakes generally considered adequate. So effects of Mg-deficiency are exacerbated by high protein intake.

    And what is about mad cow disease (BSE) and a high protein intake?.
    See a nutritional experiment performed in England; published in Veterinary Record (MOORBY et al., 2000) and in Journal of Dairy Science ( DEWHURST et al., 2000; MOORBY et al., 2000).  There six from the 47 experimental dairy cows developed clinical signs of BSE; after six month incubation period (about 20% of crude protein in the dairy ration) ; without meat and bone meal, however, with high protein concentrate feeding.
          In connection with the protein surplus, ruminants are predominant about the Mg- deficiency, so BSE can be involved (www.bse-expert.cz). See these relationships, according to my recent presentation at 29th World Veterinary Congress in Vancouver (http://www.bse-expert.cz/pdf/Veter_kongres.pdf); Neurodegenerative Diseases and Schizophrenia as a Hyper or Hypofunction of the NMDA Receptors. There is the abstract about this article;
    Neurodegenerative diseases, including BSE, Alzheimer's disease etc. are caused by different mechanisms but may share a final common pathway to neuronal injury due to the overstimulation of glutamate receptors, especially of the N-methyl-D-aspartate (NMDA) receptor subtype. It is generally accepted that the influx of Ca as a result of excessive activation of the NMDA receptor underlies the toxic actions of glutamate in many systems. Also, ammonia intoxication leads to excessive activation of NMDA receptors in brain. On the other hand, Mg competes with Ca at voltage- gated calcium channels both intracellularly and on the cell surface membrane. So, Mg can protect against NMDA- induced neurodegeneration and Ca deficiency can be important about "NMDA hypofunction" in schizophrenia. There are no scientific references to date in which high intake of crude protein (and potassium) high enough to lead to a state of hyperammonemia (and hypomagnesemia) during the incubation period of the BSE. Therefore there is the first idea of this review; to show the hyperammonemia plus hypomagnesemia"simultaneous" action on the ruminant tissues. Recently was found that elevated manganese in blood was associated with "prion infection" in ruminants. These findings about "manganese theory" act in concert with this "BSE ammonia- magnesium theory".
    Josef Hlasny, DVM, PhD., veterinary surgeon in Bludov, Czech Republic

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Renaissance of "food as medicine" in modern clinical trials